The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wigwammer,
As far as i am aware, they are joint holders 50/50 With the CNRS...
Wildbunch will surely clarify this :-)
Nolupus,
Certain details lacking from your post too. What percentage of the patent do immupharma own?
Cautious optimism growing , steady low volume buying with very few sells today and climbing the share risers table, bulls could be moving in .
3.0p coming
A bit lukewarm but I remain cautiously optimistic that the P3 trial will result in a drug coming to market for Lupus patients which in return should see a multi bag sp gain from here. Protecting the IP just good housekeeping, results or not from the P3 trial will determine where the sp goes.
Wigwammer,
Whilst we may agree on certain details ( or lack of )
One should remember that IMM are only one of the joint patent holders .
It’s even more bizarre that Avion have sustained interest, without any clear strategy to protect the IP. Perhaps they are just not telling us what they know? I hope so, because what we do know is they currently have little protection.
Well of course. Not much point having IP if it isn’t protected. Have they only just considered this?! So where is the detail on how they plan to do it… it’s just a very strange RNS.
Wig
Maybe its what a potential partner has asked for. Dotting the i*s and crossing the t's.
Protection ois essential in this game.
Gla
Initiating a patent protection strategy?! Well yes, patent protection is a good idea if you’re an IP based company. Almost no detail whatsoever about how they plan to do it. Strange and bizarre communication.
Maybe thats what the potential partners want before they seal the deal.
Remember we going for 2 indications with this drug.
Back to work for me after 2 weeks off.
Gla
They have discussions with a deal looks like.
He he he he.
Quite close Nolupus or should I say Tim ?
Yes but for good reason, extending patent life suggests the company and its backers expect the next Phase 3 trial to produce results.
UP WE GO
Hope everyone had a nice relaxing BH and Easter
Frits. Everyone is entitled to an opinion. Nolupus makes a valid point.
Nobinpus,
By your own admission, you have stated several times that you are not invested in IMM! Stop changing the story to suit your negative passive aggressive narrative.
Frits
Wildbunch,
They may be awaiting on some patent news before concluding any major deal..
Let's wait and see
Absolutely agree with you wildbunch.
Thats the transparency we need and deserve as shareholders.
Gla
I think that we need more information about the Lupus trial timetable. This will help negotiations for the ROTW rights. Also orphan status etc for CIDP.
As a side issue INC alone could be worth circa 5p in the shortish term.
Look forward to seeing more investors at this AGM.
GLA
GLA
Absolute bargain, but dont you just get tje feeling that it will pop 🤣🎊
....£M9.16. Still laughable. A great BUY.
Regardless, we want IMM to be successful because we want to improve the quality of life of our patients.
Gla
Nolupus
Both-actually I am going to stop wasting my time looking at your posts. Same old-same old.
Goodbye and best of luck with any investments you have.